Analytical instruments, medical and industrial doing well. Guidance raised for the 3rd time. Down from peak valuation. Not compellingly cheap, but worth looking at from a long-term perspective.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.